Investment summary

Topotarget is only developing belinostat, which is partnered with Spectrum Pharmaceuticals. The drug is in a pivotal Phase II trial, BELIEF, for peripheral T-cell lymphoma (PTCL), which should render results in H112. If positive, this could lead to the drug's approval in the US in 2013. Belinostat is also being developed for cancer of unknown primary (CUP) and non-small cell lung cancer (NSCLC). Data from a Phase II study in CUP are expected in H112 and two Phase II studies in NSCLC are underway. Spectrum is buying another company with a drug for PTCL, but says it is still committed to developing belinostat. Topotarget's net cash position was DKK124m (c $22m) at FY11, which should enable the company to operate into Q213.

Last updated on 23/04/2012

Industry outlook

Topotarget's belinostat belongs to the class of drugs called histone deacetylase inhibitors (HDACi). Two such drugs have been approved and nine others are in clinical development. However, belinostat has a favourable safety profile and could be the first HDACi approved for the treatment of solid tumours in combination therapy.

Last updated on 23/04/2012